Ophthalmology CROs

Gene therapy and viral vector CDMO in Columbus, Ohio, with 20+ years of leadership and 500+ GMP drug substance batches produced for rare and ultra-rare disease programs.

Global CRO built exclusively for MedTech, integrating regulatory strategy, clinical development, and market access reimbursement for device and IVD programs from the Netherlands since 1988.

Global clinical trial technology and endpoint services company providing cardiac safety (ECG), respiratory, imaging, patient-reported outcomes, and clinical event adjudication for pharma and biotech sponsors.

Contract research organization specializing in clinical research support for US government agencies including NIH, providing data management, biostatistics, and clinical operations for federally funded trials.

Global tech-enabled full-service CRO with strength in government-sponsored trials, infectious disease, vaccines, ophthalmology, and rare disease clinical development.

Specialist preclinical ophthalmology CRO with AAALAC-accredited labs in Oklahoma City and Ann Arbor, providing pharmacology, PK/tox, bioanalysis, and formulation services for ocular drug development.

Retina-specialty CRO with offices across Latin America, Asia, and Australia supporting clinical trials in 18+ countries for ophthalmic and rare disease indications.

World-leading ophthalmology-specialized CRO conducting preclinical and clinical research from ocular surface to posterior segment, with 70+ ocular drugs and devices brought to market.

Next-generation decentralized CRO from London using a proprietary clinical trial platform to deliver faster, more efficient trials in cardiovascular, oncology, and ophthalmology.

Australian boutique CRO specialising in early-phase and first-in-human MedTech clinical trials across Australia, New Zealand, and the USA.

French CDMO specialising in topical, semi-solid, and liquid pharmaceutical manufacturing for clinical trial supply and commercial production.

World's leading ophthalmology-specialized CRO providing full-service clinical development from Phase I through Phase IV exclusively for ophthalmic therapeutics, devices, and surgical products.

Gene therapy-focused CDMO providing viral vector manufacturing for adeno-associated virus (AAV) gene therapies, acquired by Catalent to expand biologics capabilities.

Specialty preclinical CRO focused on non-GLP ophthalmic and oncology efficacy studies, providing in vivo animal model services for ocular disease and solid tumor drug development.

Full-service CRO founded on biostatistics and data science excellence, supporting Phase I-IV trials across rare disease, immunology, and ophthalmology from Research Triangle Park.

Full-service contract research and consulting organization providing clinical trial management, biostatistics, data management, and regulatory services with particular expertise in rare disease and pediatrics.

Full-service CRO providing clinical research, biostatistics, data management, and regulatory services with particular expertise in ophthalmology, CNS, and rare disease.

Mid-size CRO specializing in clinical development for small and emerging biotech companies. Now part of Allucent, offering Phase 1–3 trial management and regulatory consulting.

Innovation CRO purpose-built for medical device and IVD development, delivering integrated regulatory, clinical, and laboratory services across cardiovascular, neurological, and ophthalmic indications.

Tech-enabled next-generation CRO offering faster and lower-cost clinical trials powered by proprietary software, targeting biotech sponsors in dermatology, oncology, and ophthalmology.

UK-based specialist CRO for ophthalmic and contact lens clinical trials, providing study design, clinical monitoring, and regulatory support for eye care medical devices and pharmaceutical products.